Literature DB >> 21246527

Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.

Henning Jann1, Stephanie Roll, Anne Couvelard, Olivia Hentic, Marianne Pavel, Jacqueline Müller-Nordhorn, Martin Koch, Christoph Röcken, Guido Rindi, Philippe Ruszniewski, Bertram Wiedenmann, Ulrich-Frank Pape.   

Abstract

BACKGROUND: Prognostic classification of neuroendocrine tumor (NET) patients is difficult due to the complexity of current classification systems. A recent proposal for a tumor-node-metastasis (TNM) classification and a grading system based on the proliferative fraction proved valid in NETs of foregut origin. The purpose of this study was to test the efficacy of a proposal for TNM staging and grading for midgut and hindgut NETs.
METHODS: Two hundred seventy patients with histologically proven midgut and hindgut NETs were investigated. Epidemiological, clinicopathological, and tumor-specific data at initial diagnosis were recorded. Tumors were classified according to the World Health Organization (WHO) and the recent European Neuroendocrine Tumor Society-TNM staging and grading proposal. Survival analysis and statistical testing for independent prognostic factors were performed using log-rank tests and Cox regression.
RESULTS: Of 270 NETs originating in the midgut or hindgut, 7% (5-year survival rate [YSR], 100%) were stage 1, 8% (5-YSR, 100%) were stage 2, 19% (5-YSR, 89.5%) were stage 3, and 66% (5-YSR, 83.3%) were stage 4 NETs; 62% (5-YSR 95.2%) were grade 1, 32% (5-YSR 82.0%) were grade 2, and 6% (5-YSR, 51.4%) were grade 3 NETs. WHO classification significantly separated poorly from well-differentiated NET or carcinomas but did not further discriminate. TNM staging significantly separated stages 1, 2, and 3 from stage 4 NETs, as did grading according to proliferative capacity for all grades. Multivariate analysis confirmed these results, particularly for Ki67 grading.
CONCLUSIONS: The acquired data confirmed the prognostic relevance of the proposed TNM staging and grading system and demonstrated the applicability of these classification tools. The TNM system can therefore facilitate therapeutic stratification and comparison of data from different institutions.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21246527     DOI: 10.1002/cncr.25855

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  74 in total

1.  Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.

Authors:  Christina L Roland; Aihua Bian; John C Mansour; Adam C Yopp; Glen C Balch; Rohit Sharma; Xian-Jin Xie; Roderich E Schwarz
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

2.  CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention.

Authors:  Nehara Begum; Ulrich Wellner; Christoph Thorns; Georg Brabant; Martin Hoffmann; Conny Georg Bürk; Hendrik Lehnert; Tobias Keck
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

3.  Long-term complete remission of a patient with high grade neuroendocrine carcinoma of ampulla of Vater.

Authors:  Farzad Taghizadeh-Hesary; Afshin Moradi; Mona Malekzadeh
Journal:  BMJ Case Rep       Date:  2018-06-27

4.  IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.

Authors:  Sara Massironi; Alessandro Del Gobbo; Federica Cavalcoli; Stefano Fiori; Dario Conte; Alessio Pellegrinelli; Massimo Milione; Stefano Ferrero
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

Review 5.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors.

Authors:  Michelle Kang Kim; Richard R P Warner; Sasan Roayaie; Noam Harpaz; Stephen C Ward; Steven Itzkowitz; Juan P Wisnivesky
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

7.  Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor.

Authors:  Martha Frances Wright; Justin Cates; Raul S Gonzalez; Satya Das; Jordan D Berlin; Chanjuan Shi
Journal:  Am J Surg Pathol       Date:  2019-04       Impact factor: 6.394

Review 8.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 9.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

10.  Carcinoma-like nonfunctional pheochromocytoma in the right adrenal gland: A case report.

Authors:  Shingo Moriyama; Hideki Takeshita; Saori Araki; Takuo Tokairin; Makoto Kagawa; Koji Chiba; Akiko Adachi; Akira Noro
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.